What's Going On With Alnylam Stock On Friday?

Core Insights - Alnylam Pharmaceuticals' stock has seen significant gains, with a year-to-date increase of 92.6% and a 58.7% rise over the last six months [2] - The company reported a strong third-quarter performance with adjusted earnings of $2.90, a notable recovery from a loss of $0.50 a year ago, and quarterly sales of $1.25 billion, reflecting a 149% year-over-year increase [2] - Alnylam raised its fiscal 2025 sales guidance to a range of $3.6 billion to $3.8 billion, surpassing the consensus estimate of $3.53 billion [3] Performance and Earnings - The adjusted earnings for Q3 2025 were $2.90, compared to a loss of $0.50 in the same quarter last year, exceeding analysts' expectations of $0.75 [2] - Quarterly sales reached $1.25 billion, significantly above the consensus of $977.79 million, marking a 149% increase year-over-year [2] - Sales of Amvuttra surged by 165% to $685.30 million [2] Analyst Outlook - Chardan Research and William Blair provided positive outlooks for Alnylam following the second-quarter results, highlighting the strong launch of Amvuttra for ATTR-CM [4] - ATTR-CM is identified as a rare and often underdiagnosed form of heart failure, indicating a significant market opportunity for Alnylam [4] Clinical Developments - Alnylam announced new post hoc analyses from the HELIOS-B Phase 3 study of Amvuttra, showing promising results [5] - A mixed model analysis indicated that treatment with vutrisiran monotherapy led to statistically significant improvements in cardiac structure and function compared to placebo [6] - At Year 3, 22% of patients treated with vutrisiran showed amyloid regression, while no patients in the placebo group exhibited this outcome [7]